Global biotechnology firm CSL (ASX:CSL) has broken ground on a $1.5 billion expansion of its manufacturing facility in Kankakee, marking a significant milestone in the company’s international growth strategy.
The project is designed to drastically scale the production of life-saving plasma-derived therapies, addressing a rising global demand for treatments targeting rare and serious diseases.
Once complete, the upgraded site will bolster the supply of albumin and specialised medicines used to treat critical conditions such as haemophilia, primary immunodeficiency, and hereditary angioedema.
Beyond the immediate clinical benefits, the expansion is projected to generate at least 300 high-skilled pharmaceutical positions, supported by approximately 800 construction and ancillary roles during the development phase.
The investment reinforces CSL's long-term commitment to its American operations; since 2018, the company has poured over $3 billion into US infrastructure.
The latest venture brings CSL's domestic workforce to nearly 19,000 employees, representing roughly 60% of its global staff.
Construction is slated to continue over several years, with the facility expected to be fully operational by 2031.
As the biotech sector faces increasing pressure to secure supply chains for plasma products, this Illinois expansion serves as a cornerstone for CSL's mission to deliver sustainable healthcare solutions for trauma and chronic illness patients worldwide.